Cryo Cell International INC

Cryo-Cell International has received approval from the NYSE American for a compliance plan to address listing deficiencies, extending its deadline to September 9, 2027.

Cryo-Cell International received a notice from NYSE American indicating non-compliance with continued listing standards due to a stockholders deficit and recent net losses.

Cryo-Cell International, Inc. announced it will not declare a quarterly cash dividend for the fourth quarter of fiscal 2025, citing future decisions will depend on financial performance and strategic priorities.

Cryo-Cell International amended its credit agreement with Susser Bank, extending maturity dates for its revolving credit and term loans while adjusting credit limits and interest margins.

Cryo-Cell International, Inc. announced the dates for its 2025 Annual Meeting of Stockholders, including the meeting date, record date, and deadlines for stockholder proposals.

Cryo-Cell International received a termination notice from Duke University for their Patent and Technology License Agreement, citing a breach of contract.

Cryo-Cell International reports a 2% revenue decrease for the quarter ended May 31, 2026, amidst ongoing arbitration with Duke University and NYSE listing concerns.

Cryo-Cell International, Inc. reported a decrease in revenue for the first quarter of fiscal year 2026, primarily due to lower public banking revenue and a slight dip in processing and storage fees, while SG&A expenses increased due to legal fees.

Cryo-Cell International reports a decrease in Q3 2025 revenue and net income, alongside escalating legal disputes with Duke University impacting future growth plans.

Cryo-Cell International, Inc. reported a significant decline in net income for the six months ended May 31, 2025, primarily impacted by increased expenses and the termination of its crucial license agreement with Duke University, which has halted key strategic growth initiatives.

Cryo-Cell International's Q1 2025 revenue increased slightly, but the company faces ongoing legal challenges and uncertainties regarding its Duke University license agreement.

Cryo-Cell International has filed an amendment to its quarterly report to update disclosures regarding an ongoing legal proceeding.

Cryo-Cell International, Inc. reported a net loss of $2.43 million for fiscal year 2025, a significant decline from the previous year's profit, primarily due to an impairment charge on public inventory and ongoing litigation with Duke University.

Cryo-Cell International's 10-K filing reveals a 2% revenue increase for fiscal year 2024, overshadowed by an ongoing arbitration with Duke University and strategic shifts in business operations.

Cryo-Cell International, Inc. released its annual 10-K report, outlining its financial performance, strategic initiatives, and risk factors for the fiscal year ended November 30, 2023.

Cryo-Cell International's Chairman and Co-CEO, David Portnoy, reported new stock option grants and updated his beneficial ownership of common stock and derivative securities.

Cryo-Cell International's Chief Information Officer, Oleg Mikulinsky, reported new stock option grants and existing beneficial ownership of common stock and derivative securities.

Cryo-Cell International Co-CEO Mark L. Portnoy reported new stock option grants and updated his beneficial ownership, including performance-based vesting conditions.

Cryo-Cell International's VP Finance and CFO, Jill M. Taymans, was granted 30,000 stock options with performance-based vesting conditions.

Cryo-Cell International's Chairman and Co-CEO, David Portnoy, reported recent acquisitions of common stock, increasing his beneficial ownership.

Cryo-Cell International Co-CEO David Portnoy increased his direct beneficial ownership of common stock through open market purchases in mid-November 2025.

Cryo-Cell International, Inc. announced its 2025 Annual Meeting of Stockholders to be held on October 21, 2025, focusing on director elections, auditor ratification, and executive compensation.

Cryo-Cell International will hold its annual stockholder meeting on October 29, 2024, to elect directors, ratify the appointment of auditors, and conduct an advisory vote on executive compensation.

Camac Partners, LLC and affiliated entities have filed an amended Schedule 13D, disclosing beneficial ownership of approximately 6.8% of Cryo-Cell International Inc.'s common stock.

Camac Partners and affiliates have disclosed a 5.3% beneficial ownership stake in Cryo-Cell International, Inc., citing undervaluation and plans for strategic engagement.